Cerus Co. (NASDAQ:CERS - Get Free Report) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.89 and traded as high as $2.07. Cerus shares last traded at $1.98, with a volume of 1,200,281 shares trading hands.
Wall Street Analyst Weigh In
Separately, Stifel Nicolaus cut their target price on Cerus from $6.00 to $3.00 and set a "buy" rating on the stock in a research note on Thursday, October 17th.
View Our Latest Stock Report on Cerus
Cerus Stock Performance
The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The firm has a market cap of $334.28 million, a price-to-earnings ratio of -16.36 and a beta of 1.29. The firm has a fifty day simple moving average of $1.75 and a two-hundred day simple moving average of $1.88.
Insiders Place Their Bets
In related news, Director Eric Bjerkholt sold 20,000 shares of Cerus stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $1.78, for a total transaction of $35,600.00. Following the completion of the sale, the director now owns 162,133 shares of the company's stock, valued at $288,596.74. The trade was a 10.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 3.40% of the company's stock.
Institutional Investors Weigh In On Cerus
Institutional investors and hedge funds have recently modified their holdings of the company. Sei Investments Co. raised its position in Cerus by 658.9% during the second quarter. Sei Investments Co. now owns 263,839 shares of the biotechnology company's stock valued at $464,000 after acquiring an additional 229,074 shares in the last quarter. AQR Capital Management LLC raised its position in Cerus by 938.5% during the second quarter. AQR Capital Management LLC now owns 215,901 shares of the biotechnology company's stock valued at $380,000 after acquiring an additional 195,112 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Cerus by 10.9% in the second quarter. The Manufacturers Life Insurance Company now owns 73,372 shares of the biotechnology company's stock valued at $129,000 after buying an additional 7,209 shares in the last quarter. Algert Global LLC purchased a new stake in shares of Cerus in the second quarter valued at approximately $97,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Cerus in the third quarter valued at approximately $121,000. Institutional investors and hedge funds own 78.37% of the company's stock.
Cerus Company Profile
(
Get Free Report)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Recommended Stories
Before you consider Cerus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cerus wasn't on the list.
While Cerus currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
